Diffusion Denoised Smoothing for Certified and Adversarial Robust Out-Of-Distribution Detection

As the use of machine learning continues to expand, the importance of ensuring its safety cannot be overstated. A key concern in this regard is the ability to identify whether a given sample is from the training distribution, or is an "Out-Of-Distribution" (OOD) sample. In addition, adversaries can manipulate OOD samples in ways that lead a classifier to make a confident prediction. In this study, we present a novel approach for certifying the robustness of OOD detection within a $\ell_2$-norm around the input, regardless of network architecture and without the need for specific components or additional training. Further, we improve current techniques for detecting adversarial attacks on OOD samples, while providing high levels of certified and adversarial robustness on in-distribution samples. The average of all OOD detection metrics on CIFAR10/100 shows an increase of $\sim 13 \% / 5\%$ relative to previous approaches

Benchmarking the Variational Quantum Eigensolver using different quantum hardware

The Variational Quantum Eigensolver (VQE) is a promising quantum algorithm for applications in chemistry within the Noisy Intermediate-Scale Quantum (NISQ) era. The ability for a quantum computer to simulate electronic structures with high accuracy would have a profound impact on material and biochemical science with potential applications e.g., to the development of new drugs. However, considering the variety of quantum hardware architectures, it is still uncertain which hardware concept is most suited to execute the VQE for e.g., the simulation of molecules. Aspects to consider here are the required connectivity of the quantum circuit used, the size and the depth and thus the susceptibility to noise effects. Besides theoretical considerations, empirical studies using available quantum hardware may help to clarify the question of which hardware technology might be better suited for a certain given application and algorithm. Going one step into this direction, within this work, we present results using the VQE for the simulation of the hydrogen molecule, comparing superconducting and ion trap quantum computers. The experiments are carried out with a standardized setup of ansatz and optimizer, selected to reduce the amount of iterations required. The findings are analyzed considering different quantum processor types, calibration data as well as the depth and gate counts of the circuits required for the different hardware concepts after transpilation.Comment: Submitted to the IEEE for possible publicatio

Recommending Solution Paths for Solving Optimization Problems with Quantum Computing

Solving real-world optimization problems with quantum computing requires choosing between a large number of options concerning formulation, encoding, algorithm and hardware. Finding good solution paths is challenging for end users and researchers alike. We propose a framework designed to identify and recommend the best-suited solution paths. This introduces a novel abstraction layer that is required to make quantum-computing-assisted solution techniques accessible to end users without requiring a deeper knowledge of quantum technologies. State-of-the-art hybrid algorithms, encoding and decomposition techniques can be integrated in a modular manner and evaluated using problem-specific performance metrics. Equally, tools for the graphical analysis of variational quantum algorithms are developed. Classical, fault tolerant quantum and quantum-inspired methods can be included as well to ensure a fair comparison resulting in useful solution paths. We demonstrate and validate our approach on a selected set of options and illustrate its application on the capacitated vehicle routing problem (CVRP). We also identify crucial requirements and the major design challenges for the proposed automation layer within a quantum-assisted solution workflow for optimization problems.Comment: Reviewed and published at IEEE QSW 202

Efficient learning of Sparse Pauli Lindblad models for fully connected qubit topology

The challenge to achieve practical quantum computing considering current hardware size and gate fidelity is the sensitivity to errors and noise. Recent work has shown that by learning the underlying noise model capturing qubit cross-talk, error mitigation can push the boundary of practical quantum computing. This has been accomplished using Sparse Pauli-Lindblad models only on devices with a linear topology connectivity (i.e. superconducting qubit devices). In this work we extend the theoretical requirement for learning such noise models on hardware with full connectivity (i.e. ion trap devices).Comment: 6 pages, 3 figure

Quantum-Assisted Solution Paths for the Capacitated Vehicle Routing Problem

Many relevant problems in industrial settings result in NP-hard optimization problems, such as the Capacitated Vehicle Routing Problem (CVRP) or its reduced variant, the Travelling Salesperson Problem (TSP). Even with today's most powerful classical algorithms, the CVRP is challenging to solve classically. Quantum computing may offer a way to improve the time to solution, although the question remains open as to whether Noisy Intermediate-Scale Quantum (NISQ) devices can achieve a practical advantage compared to classical heuristics. The most prominent algorithms proposed to solve combinatorial optimization problems in the NISQ era are the Quantum Approximate Optimization Algorithm (QAOA) and the more general Variational Quantum Eigensolver (VQE). However, implementing them in a way that reliably provides high-quality solutions is challenging, even for toy examples. In this work, we discuss decomposition and formulation aspects of the CVRP and propose an application-driven way to measure solution quality. Considering current hardware constraints, we reduce the CVRP to a clustering phase and a set of TSPs. For the TSP, we extensively test both QAOA and VQE and investigate the influence of various hyperparameters, such as the classical optimizer choice and strength of constraint penalization. Results of QAOA are generally of limited quality because the algorithm does not reach the energy threshold for feasible TSP solutions, even when considering various extensions such as recursive, warm-start and constraint-preserving mixer QAOA. On the other hand, the VQE reaches the energy threshold and shows a better performance. Our work outlines the obstacles to quantum-assisted solutions for real-world optimization problems and proposes perspectives on how to overcome them.Comment: Submitted to the IEEE for possible publicatio

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be targeted by the CD38 antibody daratumumab (DARA), approved for the treatment of multiple myeloma. Tumor cell killing by myeloid cells is relevant for the efficacy of many therapeutic antibodies and can be more efficacious with human IgA than with IgG antibodies. This is demonstrated here by investigating antibody-dependent cellular phagocytosis (ADCP) by macrophages and antibody-dependent cell-mediated cytotoxicity (ADCC) by polymorphonuclear (PMN) cells using DARA (human IgG1) and an IgA2 isotype switch variant (DARA-IgA2) against T-ALL cell lines and primary patient-derived tumor cells. ADCP and ADCC are negatively regulated by interactions between CD47 on tumor cells and signal regulatory protein alpha (SIRPα) on effector cells. In order to investigate the impact of this myeloid checkpoint on T-ALL cell killing, CD47 and glutaminyl-peptide cyclotransferase like (QPCTL) knock-out T-ALL cells were employed. QPTCL is an enzymatic posttranslational modifier of CD47 activity, which can be targeted by small molecule inhibitors. Additionally, we used an IgG2σ variant of the CD47 blocking antibody magrolimab, which is in advanced clinical development. Moreover, treatment of T-ALL cells with all- trans retinoic acid (ATRA) increased CD38 expression leading to further enhanced ADCP and ADCC, particularly when DARA-IgA2 was applied. These studies demonstrate that myeloid checkpoint blockade in combination with IgA2 variants of CD38 antibodies deserves further evaluation for T-ALL immunotherapy

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570